AltruBio is committed to the development of innovative treatments and prevention against inflammatory/autoimmune disease. Through the advancement of our technology platforms we aim to:
b2/2022011921194434ei369Mj1.png)
AltruBio is developing first-in-class immune-modulators to target diseases of the immune system. Its world-class global team brings a breadth of expertise in immunology and drug development to bring their biologic treatments to patients.
b2/20221216154816misufdavt1.jpg)
AltruBio has clinically validated a first-in-class immune checkpoint regulator program to selectively target unwanted T-cells. It enhances the immune response system to deplete chronically activated T-cells and treat diseases of the immune system.
b1/20180926140339derklsb0P1.png)
Neihulizumab is a first-generation PSGL-1 agonist with clinically validated safety, efficacy and durability demonstrated across multiple Phase 1 and Phase 2 trials. ALTB-268, our next-generation PSGL-1 agonist, has an improved target product profile including increased potency and potential for subcutaneous dosing allowing for expansion to new indications.
AltruBio is committed to the development of innovative treatments and prevention against inflammatory/autoimmune disease. Through the advancement of our technology platforms we aim to:
Creating better therapies for patients with immune diseases